B
Bryan Burmeister
Researcher at Princess Alexandra Hospital
Publications - 163
Citations - 8693
Bryan Burmeister is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Radiation therapy & Chemoradiotherapy. The author has an hindex of 39, co-authored 158 publications receiving 7908 citations. Previous affiliations of Bryan Burmeister include Sir Charles Gairdner Hospital & University of Queensland.
Papers
More filters
Journal ArticleDOI
Development of the Melanoma Concerns Questionnaire© (MCQ‐28©); refinement of the EORTC QLQ‐MEL38 Module
Julie Winstanley,Edward White,Robyn P. M. Saw,Teresa Young,Bryan Burmeister,Dejan Nikolic,Iria Busto‐Cornide,Nicolás Iglesias‐Pena,Frances M. Boyle +8 more
TL;DR: The aim of this study was to further test the hypothesised domain structure and psychometric properties of the phase 3 module, in a new larger sample of melanoma patients.
Journal ArticleDOI
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum
Bryan Burmeister,David Schache,Elizabeth Burmeister,Andrew Bell,Michael Poulsen,Euan Walpole,John A. Mackintosh +6 more
TL;DR: The combined adjuvant postoperative chemoradiation therapy using this protocol is effective but has significant acute and late morbidity.
Journal ArticleDOI
Localization of small esophageal cancers for radiation planning using endoscopic contrast injection: report on a series of eight cases.
TL;DR: A series of eight patients with small esophageal cancers in whom the tumors were successfully localized following endoscopic injection of contrast, and treated with chemoradiation therapy demonstrated that conventional techniques are mostly unreliable when applied to very early cancers.
Journal ArticleDOI
Targeted therapy and chemoradiotherapy in oesophageal cancer
TL;DR: This proposal uses a principle commonly applied to non-inferiority trials but not to superiority trials to mitigate the risk of introducing into clinical practice drugs that in reality have no effect on survival, and discourages the development of new drugs that add only marginal benefi ts over what is already available.
Journal ArticleDOI
T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
P. Mackenzie,David Pryor,David Pryor,Elizabeth Burmeister,Matthew Foote,Matthew Foote,Benedict Panizza,Bryan Burmeister,Bryan Burmeister,Sandro V. Porceddu,Sandro V. Porceddu +10 more
TL;DR: T-category is more predictive of distant relapse and may provide additional prognostic value for LRR and death when accounting for HPV status, and tumour HPV status was the strongest predictor of L RR and death.